More frequent routine primary care visits for certain higher-risk commercially insured adults are associated with lower net population-level health care costs.
- By Martha Deja, Nicholas Buhay, Marc Herant, and Jason Brauner
Denali Therapeutics’ recent accelerated approval of AVLAYAH, an enzyme replacement therapy for Hunter syndrome (MPS II), is a milestone accomplishment in blood brain barrier (BBB)-crossing technology.…